Funds will be used for general corporate purposes, including expenses related to the potential commercialization of OMS302 for intraocular lens replacement, as well as for R&D expenses such as funding planned clinical trials for its OMS103HP, PDE10, MASP-2 and PDE7 programs...Proceeds also may be used to fund preclinical studies, capital expenditures, working capital and to advance the firm's potential products toward commercialization

The funds will support clinical work in multiple sclerosis (MS), inflammatory bowel disease (IBD) and allergic/immune-mediated disorders. (See BioWorld Today, April 8, 2013.) The pricing hits pretty close to the $86.3 million target set when the company filed for its offering only a month ago...Net proceeds will be used primarily for working capital, R&D and general corporate purposes

The drug has gone through 12 clinical trials in more than 1,400 subjects already, showing that it knocks down serum bile acid levels safely...Also in the pipeline: Lumena has licensed the patent rights and a package of clinical and non-clinical data for LUM002, another inhibitor of ASBT, also previously in development at the Phase I stage as a cholesterol-lowering agent by Paris-based Sanofi SA...Lumena plans to complete the Phase I clinical program of LUM002 in healthy volunteers later this year

Net proceeds will be used to support R&D activities, working capital and general corporate purposes...The funding allowed ReXceptor to enter a formal partnership with C2N Diagnostics, which will assist the company with the initiation and coordination of the clinical trial of an AD program licensed from Case Western's Technology Transfer Office and based on discoveries that bexarotene, a medication sold at Targretin for cutaneous T-cell lymphomas, reversed AD symptoms in mice within 72 hours of a

AG014 comprises oral delivery of an anti-TNF antibody with proven clinical efficacy in IBD, resulting in local efficacy and an improved safety profile over systemic drugs...The company, which ended the first quarter with about $7.4 million in cash, equivalents and working capital, has prioritized work on MN-166 (ibudilast), which is in Phase I and Phase II studies for drug dependence and pain, largely through investigator-sponsored trials...Shares of Northwest (NASDAQ:NWBO) fell 13 cents to close

Proceeds will be used for servicing long-term debt and working capital...Canbex, a spinout of University College London, has said it expects to start clinical testing this year

Another $406 million could come in the form of clinical, regulatory and commercial milestones, and Enanta would be eligible for tiered, double-digit royalties and a U.S...Net proceeds are expected to support clinical trial costs and acquisition of manufacturing equipment, leasehold improvements and general corporate purposes...Trimel's pipeline includes CompleoTRT, a bioadhesive intranasal testosterone gel for male hypogonadism.

Cerus anticipates using the net proceeds for clinical development and other R&D activities related to the Intercept Blood System, preparatory activities for the potential commercialization of the system in the U.S...and elsewhere, and for other general corporate purposes, including regulatory activity, selling, general and administrative expenses and working capital

Proceeds will be used to fund clinical trials of IMO-8400, an agonist of Toll-like receptors 7, 8 and 9, which is in development for autoimmune and inflammatory diseases, as well as for working capital and other general corporate purposes

The company plans to use proceeds from the offering to complete clinical development of Ravicti in hepatic encephalopathy (HE) and to fund post-approval studies in UCD...Durata Therapeutics Inc., of Chicago, disclosed in its 2012 financial results that it entered a $20 million debt facility on March 5, with Oxford Finance LLC, with net proceeds expected to be received by the end of this month and used for working capital purposes...at the same unit price.

Proceeds will be used to support continuing clinical development of Ravicti (glycerol phenylbutyrate) in HE, a brain disorder caused by chronic liver failure...Funds also will support postmarketing studies in urea cycle disorders (UCD) and working capital and general corporate purposes

Funds will be used to support clinical trials and for working capital and general corporate purposes. (See BioWorld Today, Feb. 7, 2013

The net proceeds will be used for working capital and general corporate purposes, including the continuation of the Abili-T clinical study, Opexa's ongoing Phase IIb trial of Tcelna in secondary progressive multiple sclerosis patients

The company will receive proceeds of $8 million, which it expects to use to fund clinical trials and for working capital and general corporate purposes.

Net proceeds will be used for general corporate purposes, including R&D activities, capital expenditures and working capital...DelMar is working on a cancer drug pipeline, including lead asset VAL-083, which is in clinical trials in refractory glioblastoma multiforme

The primary efficacy endpoint will be clinical improvement in the Systemic Lupus Erythematosus Responder Index (SRI-8...Net proceeds are expected to support general corporate purposes, including working capital, R&D, clinical trials and capital expenditures...Net proceeds will be used for general corporate and working capital purposes, primarily to accelerate commercialization of several of the firm's genetic tests

Gross proceeds totaled about $34.1 million and will be used for general corporate purposes, including clinical trial, preclinical and other R&D expenses, capital expenditures, working capital and general and administrative costs

Funds will be used for working capital and for continuation of clinical research and development of Cavatak, an oncolytic virus candidate

Going into the NRAS population isn't surprising, given the promising Phase II data reported at the American Society of Clinical Oncology (ASCO) meeting earlier this year...Over the summer, it hit its primary endpoint of reducing pain more effectively than placebo in a Phase II trial in osteoarthritis. (See BioWorld Today, Aug. 2, 2012.) Proceeds from the public offering – funds could increase by about $9.9 million if underwriters exercise their 2.7 million-share overallotment option in full – are